Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | FLT3/CD3 Fabsc antibody |
Synonyms | |
Therapy Description |
FLT3/CD3 Fabsc antibody is a Fabsc-format bi-specific antibody that targets both FLT3 and CD3, potentially resulting in induction of T-cell activation and antibody-dependent cellular cytotoxicity against FLT3-expressing tumor cells (PMID: 25578618). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
FLT3/CD3 Fabsc antibody | Fabsc FLT3/CD3 bi-specific antibody | CD3 Antibody 99 FLT3 Antibody 5 | FLT3/CD3 Fabsc antibody is a Fabsc-format bi-specific antibody that targets both FLT3 and CD3, potentially resulting in induction of T-cell activation and antibody-dependent cellular cytotoxicity against FLT3-expressing tumor cells (PMID: 25578618). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
FLT3 exon 14 ins | acute myeloid leukemia | sensitive | FLT3/CD3 Fabsc antibody | Preclinical - Cell culture | Actionable | In a preclinical study, treatment of an acute myeloid leukemia (AML) cell lines or patient-derived xenograft (PDX)-derived AML cells harboring a heterozygous FLT3-ITD mutation with a Fabsc FLT3/CD3 bi-specific antibody resulted in near complete eradication of AML cells in culture (PMID: 28895560). | 28895560 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|